An Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Advanced or Metastatic Solid Cancer for Whom Curative Therapy is Unavailable.
Latest Information Update: 07 Mar 2012
At a glance
- Drugs Carotuximab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 02 Mar 2012 Actual end date Jun 2011 added as reported by ClinicalTrials.gov.
- 02 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jun 2011 Lead trial investigator (Bryan R Leigh) added as reported by ClinicalTrials.gov.